deltatrials
Completed PHASE1 NCT00003597

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

A Phase I Study of Thrombopoietin (rhTPO) Plus G-CSF in Children Receiving Ifosfamide, Carboplatin, and Etoposide (I.C.E.) Chemotherapy for Recurrent or Refractory Solid Tumors

Sponsor: Children's Oncology Group

Conditions Cancer
Interventions G-CSF carboplatin etoposide ifosfamide recombinant human thrombopoietin
Updated 6 times since 2017 Last updated: Jul 23, 2014 Started: Nov 30, 1998 Primary completion: Oct 31, 2004 Completion: Sep 30, 2005

This PHASE1 trial investigates Cancer and is currently completed. Children's Oncology Group leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Nov 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Oncology Group
  • National Cancer Institute (NCI)
Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States, Cincinnati, United States, Houston, United States, Indianapolis, United States, Kansas City, United States, Long Beach, United States, Los Angeles, United States, Madison, United States, Minneapolis, United States, Nashville, United States and 10 more location s